Login to Your Account

Financings Roundup

Celator Pharmaceuticals Raises $32.5M for Phase III AML Trial

By Staff Reports

Thursday, May 2, 2013
With a Phase III study on its lead investigational product, CPX-351 (cytarabine:daunorubicin) liposome Injection, currently enrolling patients, Princeton, N.J.-based Celator Pharmaceuticals Inc. said it raised $32.5 million to support the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription